Precede Biosciences closed $83.5 million in Series B financing and secured a $20 million non‑dilutive credit facility to expand capacity for its blood‑based transcriptional liquid biopsy platform. CEO Rehan Verjee said Precede is pairing next‑generation sequencing with machine learning to measure genome‑wide cancer surface protein expression and is already collaborating with pharma on roughly 30 clinical programs across modalities including ADCs and radiopharmaceuticals. Investors include Labcorp Venture Fund, UPMC Enterprises and Bristol Myers Squibb.